Evidence map›Paper›PMID 41632749›Full record

ReviewPLoS neglected tropical diseases2026

The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project: Accomplishments and ongoing research.

Peter U Fischer, Christopher L King, Philip J Budge, Gary J Weil, DOLF Consortium

Abstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Histopathological evaluation ofFrontiers in medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter U FischerDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID https://orcid.org/0000-0003-4558-3417
Christopher L KingCenter for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Philip J BudgeDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Gary J WeilDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
DOLF Consortium

Funding

Gates Foundation INV-021433Gates Foundation INV-031336
6 · The paper itself

Abstract

The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project conducts clinical and translational research to accelerate the global elimination of lymphatic filariasis (LF) and onchocerciasis (river blindness). Research needs were identified during several meetings of experts and helped study design. Over the last 15 years the project has conducted mass drug administration (MDA) studies and clinical trials with outstanding research teams in 11 countries that have led to many important discoveries. For example, DOLF studies showed that annual MDA was as effective as semiannual MDA for LF elimination and that semiannual MDA with albendazole alone can eliminate LF in areas where ivermectin cannot be safely used. Multiple studies showed that a single dose of the triple-drug combination ivermectin plus diethylcarbamazine and albendazole (IDA) was well tolerated and more effective than previously recommended treatments for LF. Results of these studies led the World Health Organization (WHO) to endorse IDA for LF elimination programs in countries without coendemic onchocerciasis or loiasis. More recently, we have shown that single-dose treatment with moxidectin plus albendazole is superior to the ivermectin plus albendazole regimen currently recommended for LF elimination in Africa. Safety and efficacy studies of combination treatments for onchocerciasis have shown that IDA is more effective against adult Onchocerca volvulus worms than ivermectin plus albendazole, although the effect was modest. We are currently testing the macrofilaricidal efficacy of other drug combinations and treatment schedules. DOLF researchers have also conducted important studies that are not clinical trials. For example, we discovered that some people with high Loa loa microfilaria (Mf, first-stage larvae) densities have cross-reactive filarial antigen tests. DOLF has also addressed the issue of MDA compliance, because improved treatments cannot be effective if people do not swallow the tablets. We highlight here some of DOLF's important discoveries that support the control and elimination of neglected tropical diseases caused by helminths.

Indexed as

Elephantiasis, FilarialFilaricidesOnchocerciasisAlbendazoleAnimalsClinical Trials as TopicDiethylcarbamazineDisease EradicationDrug Therapy, CombinationHumansIvermectinMass Drug AdministrationAlbendazoleDiethylcarbamazineFilaricidesIvermectin

Identifiers

PMID41632749
PMCPMC12867263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.